Matteo Lambertini, MD PhD· @matteolambe · X·· 2 天前评分90
正文 · 机器翻译
口头报告摘要#BreastCancer环节（#ESMO26）：TALENT 试验的最新数据表明，新辅助 #TrastuzumabDeruxtecan 在 HER2 低表达、HR+ 乳腺癌中具有活性
@OncoAlert @myESMO
542 浏览 · 20 赞 · 10 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Matteo Lambertini, MD PhD · x.com